CA2957531C - Proteines de fusion sirp alpha-anticorps - Google Patents

Proteines de fusion sirp alpha-anticorps

Info

Publication number
CA2957531C
CA2957531C CA2957531A CA2957531A CA2957531C CA 2957531 C CA2957531 C CA 2957531C CA 2957531 A CA2957531 A CA 2957531A CA 2957531 A CA2957531 A CA 2957531A CA 2957531 C CA2957531 C CA 2957531C
Authority
CA
Canada
Prior art keywords
cancer
polypeptide
domain
sirpa
immunoglobulin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2957531A
Other languages
English (en)
Other versions
CA2957531A1 (fr
Inventor
Ravindra Majeti
Emily Piccione Griffin
Original Assignee
Leland Stanford Junior University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Leland Stanford Junior University filed Critical Leland Stanford Junior University
Priority claimed from PCT/US2015/044304 external-priority patent/WO2016022971A1/fr
Publication of CA2957531A1 publication Critical patent/CA2957531A1/fr
Application granted granted Critical
Publication of CA2957531C publication Critical patent/CA2957531C/fr
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Abstract

L'invention concerne des SIRPanticorps comprenant une région variable d'immunoglobuline, qui peut se lier, de façon spécifique, à un antigène tumoral, à un antigène viral, etc., fusionnée à une séquence comprenant un domaine de liaison de SIRPa. Le domaine de liaison de SIRPa comprend au moins le domaine N-terminal semblable à l'Ig de SIRPa, et peut, en outre, comprendre d'autres séquences de SIRPa. Les SIRPanticorps peuvent être utilisés dans des procédés thérapeutiques pouvant bénéficier des activités combinées d'inhibition de l'activité de CD47 et de ciblage d'anticorps, par exemple à des fins de traitement du cancer, etc. Dans certains modes de réalisation spécifiques, le SIRPanticorps intègre une activité anti-CD20 et un domaine de liaison de SIRP ; une activité anti-CD99 et un domaine de liaison de SIRP ; ou une activité anti-TIM3 et un domaine de liaison de SIRPa.
CA2957531A 2014-08-08 2015-08-07 Proteines de fusion sirp alpha-anticorps Active CA2957531C (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462035273P 2014-08-08 2014-08-08
US62/035,273 2014-08-08
PCT/US2015/044304 WO2016022971A1 (fr) 2014-08-08 2015-08-07 Protéines de fusion sirp alpha-anticorps

Publications (2)

Publication Number Publication Date
CA2957531A1 CA2957531A1 (fr) 2016-02-11
CA2957531C true CA2957531C (fr) 2025-11-18

Family

ID=

Similar Documents

Publication Publication Date Title
US10487150B2 (en) SIRP alpha-antibody fusion proteins
US12497456B2 (en) Bispecific recombinant protein and use thereof
Zhou et al. The landscape of bispecific T cell engager in cancer treatment
Jeong et al. Novel anti-4-1BB× PD-L1 bispecific antibody augments anti-tumor immunity through tumor-directed T-cell activation and checkpoint blockade
Reichert Antibody-based therapeutics to watch in 2011
US20160235842A1 (en) Medical uses of cd38 agonists
IL294330A (en) Anti-ccr8 antibodies and their uses
JP2022116095A (ja) Ｃｄ４７及びｅｇｆｒの二重標的化による癌治療
CA3090489A1 (fr) Regime anticancereux faisant appel a des anticorps anti-cd47 et anti-cd20
EA036591B1 (ru) Способ ингибирования, замедления или уменьшения роста раковой опухоли у субъекта
EP2970447A1 (fr) Anticorps pan-elr+ cxc chimiokine
JP2017519757A (ja) 慢性リンパ球性白血病（ｃｌｌ）の処置
WO2016011069A1 (fr) Utilisations médicales d'agonistes de cd38 (anticorps)
KR20220031054A (ko) Egfrviii에 결합하는 단일클론 항체 및 이의 용도
US20230014026A1 (en) Anti-Tumor Combination Therapy comprising Anti-CD19 Antibody and Polypeptides Blocking the SIRPalpha-CD47 Innate Immune Checkpoint
CN113631230A (zh) 用于癌症治疗的脑信号蛋白-4d拮抗剂
KR20240058149A (ko) Vista 항원-결합 분자를 사용한 암의 치료 및 예방
JP2025532647A (ja) 標的分解及び治療薬の送達のための受容体介在エンドサイトーシス
WO2024148339A1 (fr) Utilisation d'un anticorps multimère anti-dr5 pour le traitement du cancer
CA2957531C (fr) Proteines de fusion sirp alpha-anticorps
US20220389104A1 (en) Method for Treating CD127-Positive Cancers by Administering an Anti-CD127 Agent
HK1238573A1 (en) Sirp alpha-antibody fusion proteins
HK1238573B (en) Sirp alpha-antibody fusion proteins
KR20220030956A (ko) Pd-1/cd3 이중 특이성 단백질에 의한 혈액암 치료
JP2020055830A (ja) 慢性リンパ球性白血病（ｃｌｌ）の処置